Niacin: From mechanisms of action to therapeutic uses

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 204-217

  Al Mohaissen, M A ^a   Pun, S C ^a   Frohlich, J J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Clinical trials; Gpr109a; High density lipoprotein; Mechanism of action; Niacin; Nicotinic acid; Receptors; Side effects

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DEXTROTHYROXINE; ESTROGEN; EZETIMIBE; FATTY ACID; G PROTEIN COUPLED RECEPTOR; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LAROPIPRANT PLUS NICOTINIC ACID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MK 0524A; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; NICOTINIC RECEPTOR;

ABDOMINAL PAIN; ACANTHOSIS NIGRICANS; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BEDTIME DOSAGE; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GOUT; HEART INFARCTION; HEART PALPITATION; HEMORRHOID; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INFLAMMATION; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; MORTALITY; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; PATIENT COMPLIANCE; PATIENT EDUCATION; PROTEIN MODIFICATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; RETINA MACULA CYSTOID EDEMA; REVIEW; SIDE EFFECT; SLOW RELEASE FORMULATION; STARVATION; STENOSIS; SUSTAINED RELEASE FORMULATION; TACHYCARDIA; URIC ACID BLOOD LEVEL; CLINICAL TRIAL; DRUG FORMULATION; METABOLISM;

CLINICAL TRIALS AS TOPIC; DRUG COMPOUNDING; HUMANS; LIPOPROTEINS, HDL; NIACIN; RECEPTORS, NICOTINIC;

EID: 77954719722     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955710791185046     Document Type: Review

References (97)

1. Altschul, R.; Hoffer, A.; Stephen, J.D. Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem., 1955, 54, 558-559.
2. Sauve, A.A. NAD+ and vitamin B3: from metabolism to therapies. J. Pharmacol. Exp. Ther., 2008, 324, 883-893.
3. Kamanna, V.S.; Kashyap, M.L. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am. J. Cardiol., 2007, 100, S53-S61.
4. Soudijn, W.; van Wijngaarden, I.; Ijzerman, A.P. Nicotinic acid receptor subtypes and their ligands. Med. Res. Rev., 2007, 27, 417-433.
5. Tunaru, S.; Kero, J.; Schaub, A.; Wufka, C.; Blaukat, A.; Pfeffer, K.; Offermanns, S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med., 2003, 9, 352-355.
6. Wise, A.; Foord, S.M.; Fraser, N.J.; Barnes, A.A.; Elshourbagy, N.; Eilert, M.; Ignar, D.M.; Murdock, P.R.; Steplewski, K.; Green, A.; Brown, A.J.; Dowell, S.J.; Szekeres, P.G.; Hassall, D.G.; Marshall, F.H.; Wilson, S.; Pike, N.B. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem., 2003, 278, 9869-9874.
7. Soga, T.; Kamohara, M.; Takasaki, J.; Matsumoto, S.; Saito, T.; Ohishi, T.; Hiyama, H.; Matsuo, A.; Matsushime, H.; Furuichi, K. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun., 2003, 303, 364-369.
8. Benyo, Z.; Gille, A.; Bennett, C.L.; Clausen, B.E.; Offermanns, S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol. Pharmacol., 2006, 70, 1844-1849.
9. Martinez, L.O.; Jacquet, S.; Esteve, J.P.; Rolland, C.; Cabezon, E.; Champagne, E.; Pineau, T.; Georgeaud, V.; Walker, J.E.; Tercé, F.; Collet, X.; Perret, B.; Barbaras, R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature, 2003, 421, 75-79.
10. van der Hoorn, J.W.; de Haan, W.; Berbee, J.F.; Havekes, L.M.; Jukema, J.W.; Rensen, P.C.; Princen, H.M. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 2016-2022.
11. Ganji, S.H.; Qin, S.; Zhang, L.; Kamanna, V.S.; Kashyap, M.L. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis, 2009, 202, 68-75.
12. Bodor, E.T.; Offermanns, S. Nicotinic acid: an old drug with a promising future. Br. J. Pharmacol., 2008, 153, S68-75.
13. Butcher, R.W.; Baird, C.E.; Sutherland, E.W. Effects of lipolytic and antilipolytic substances on adenosine 3',5'-monophosphate levels in isolated fat cells. J. Biol. Chem., 1968, 243, 1705-1712.
14. Honnor RC, Dhillon GS, Londos C. cAMP-dependent protein kinase and lipolysis in rat adipocytes. II. Definition of steady-state relationship with lipolytic and antilipolytic modulators. J. Biol. Chem., 1985, 260, 15130-15138.
15. Wang, W.; Basinger, A.; Neese, R.A.; Shane, B.; Myong, S.A.; Christiansen, M.; Hellerstein, M.K. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am. J. Physiol. Endocrinol. Metab., 2001, 280, E540-7.
16. Ganji, S.H.; Tavintharan, S.; Zhu, D.; Xing, Y. Kamanna, V.S.; Kashyap, M.L.: Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid. Res., 2004, 45, 1835-1845.
17. Jin, F.Y.; Kamanna, V.S.; Kashyap, M.L. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 1051-1059.
18. Said, H.M.; Nabokina, S.M.; Balamurugan, K.; Mohammed, Z.M.; Urbina, C.; Kashyap, M.L. Mechanism of nicotinic acid transport in human liver cells: experiments with HepG2 cells and primary hepatocytes. Am. J. Physiol. Cell. Physiol., 2007, 293, C1773-8.
19. Zhang, L.H.; Kamanna, V.S.; Zhang, M.C.; Kashyap, M.L. Niacin inhibits surface expression of ATP synthase {beta} chain in HepG2 cells: implications for raising HDL. J. Lipid. Res., 2008, 49, 1195-1201.
20. Piepho, R.W.; The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am. J. Cardiol., 2000, 86, 35L-40L.
21. Gille, A.; Bodor, E.T.; Ahmed, K.; Offermanns, S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 79-106.
22. Despres, J.P.; Lemieux, I.; Dagenais, G.R.; Cantin, B.; Lamarche, B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis, 2000, 153, 263-272.
23. Knowles, H.J.; te Poele, R.H.; Workman, P.; Harris, A.L.; Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol., 2006, 71, 646-656.
24. Illingworth, D.R.; Stein, E.A.; Mitchel, Y.B.; Dujovne, C.A.; Frost, P.H.; Knopp, R.H.; Tun, P.; Zupkis, R.V.; Greguski, R.A. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch. Intern. Med., 1994, 154,1586-95.
25. Goldberg, A.C. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am. J. Cardiol., 1998, 82, 35U-38U.
26. Morgan, J.M.; Capuzzi, D.M.; Baksh, R.I.; Intenzo, C.; Carey, C.M.; Reese, D.; Walker, K. Effects of extended-release niacin on lipoprotein subclass distribution. Am. J. Cardiol., 2003, 91, 1432-1436.
27. Cheung, M.C.; Brown, B.G.; Wolf, A.C.; Albers, J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J. Lipid. Res., 1991, 32, 383-394.
28. Vaisar, T.; Pennathur, S.; Green, P.S.; Gharib, S.A.; Hoofnagle, A.N.; Cheung, M.C.; Byun, J.; Vuletic, S.; Kassim, S.; Singh, P.; Chea, H.; Knopp, R.H.; Brunzell, J.; Geary, R.; Chait, A.; Zhao, X.Q.; Elkon, K.; Marcovina, S.; Ridker, P.; Oram, J.F.; Heinecke, J.W. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest., 2007, 117, 746-756.
29. Green, P.S.; Vaisar, T.; Pennathur, S.; Kulstad, J.J.; Moore, A.B.; Marcovina, S.; Brunzell, J.; Knopp, R.H.; Zhao, X.Q.; Heinecke, J.W. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation, 2008, 118, 1259-1267.
30. Kuvin, J.T.; Dave, D.M.; Sliney, K.A.; Mooney, P.; Patel, A.R.; Kimmelstiel, C.D.; Karas, R.H. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol., 2006, 98, 743-745.
31. Sanyal, S.; Karas, R.H.; Kuvin, J.T. Present-day uses of niacin: effects on lipid and non-lipid parameters. Expert. Opin. Pharmacother., 2007, 8, 1711-1717.
32. Atac, I.A.; Peksel, A.; Yanardag, R.; Sokmen, B.B.; Doger, M.M.; Bilen, Z.G. The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats. Drug. Chem. Toxicol., 2006, 29, 363-377.
33. Pieper, J.A. Understanding niacin formulations. Am. J. Manag. Care, 2002;8:S308-14.
34. Pieper, J.A. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am. J. Health. Syst. Pharm., 2003, 60, S9-14.
35. Capuzzi, D.M.; Guyton, J.R.; Morgan, J.M.; Goldberg, A.C.; Kreisberg, R.A.; Brusco, O.A.; Brody, J. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am. J. Cardiol., 1998, 82, 74U-81U.
36. Alsheikh-Ali, A.A.; Karas, R.H. The safety of niacin in the US Food and Drug Administration adverse event reporting database. Am. J. Cardiol., 2008, 101, 9B-13B.
37. Knopp, R.H.; Ginsberg, J.; Albers, J.J.; Hoff, C.; Ogilvie, J.T.; Warnick, G.R.; Burrows, E.; Retzlaff, B.; Poole, M. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism, 1985, 34, 642-650.
38. Knopp, R.H.; Alagona, P.; Davidson, M.; Goldberg, A.C.; Kafonek, S.D.; Kashyap, M.; Sprecher, D.; Superko, H.R.; Jenkins, S.; Marcovina, S. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism, 1998, 47, 1097-1104.
39. McCormack, P.L.; Keating, G.M. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs, 2005, 65, 2719-2740.
40. Knopp, R.H. Evaluating niacin in its various forms. Am. J. Cardiol., 2000, 21, 51L-56L.
41. Guyton, J.R.; Bays, H.E. Safety considerations with niacin therapy. Am. J. Cardiol., 2007, 99, 22C-31C.
42. Sturino, C.F.; O'Neill, G.; Lachance, N.; Boyd, M.; Berthelette, C.; Labelle, M.; Li, L.; Roy, B.; Scheigetz, J.; Tsou, N.; Aubin, Y.; Bateman, K.P.; Chauret, N.; Day, S.H.; Lévesque, J.F.; Seto, C.; Silva, J.H.; Trimble, L.A.; Carriere, M.C.; Denis, D.; Greig, G.; Kargman, S.; Lamontagne, S.; Mathieu, M.C.; Sawyer, N.; Slipetz, D.; Abraham, W.M.; Jones, T.; McAuliffe, M.; Piechuta, H.; Nicoll-Griffith, D.A.; Wang, Z.; Zamboni, R.; Young, R.N.; Metters, K.M. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)- 1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524). J. Med. Chem., 2007, 50, 794-806.
43. Cheng, K.; Wu, T.J.; Wu, K.K.; Sturino, C.; Metters, K.; Gottesdiener, K.; Wright, S.D.; Wang, Z.; O'Neill, G.; Lai, E.; Waters, M.G. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 6682-6687.
44. Lai, E.; De Lepeleire, I.; Crumley, T.M.; Liu, F.; Wenning, L.A.; Michiels, N.; Vets, E.; O'Neill, G.; Wagner, J.A.; Gottesdiener, K. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther., 2007, 81, 849-857.
45. Paolini, J.F.; Mitchel, Y.B.; Reyes, R.; Kher, U.; Lai, E.; Watson, D.J.; Norquist, J.M.; Meehan, A.G.; Bays, H.E.; Davidson, M.; Ballantyne, C.M. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am. J. Cardiol., 2008, 101, 625-630.
46. Probstfield, J.L.; Hunninghake, D.B. Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch. Intern. Med., 1994, 154, 1557-1559.
47. Grundy, S.M.; Mok, H.Y.; Zech, L.; Berman, M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid. Res., 1981, 22, 24-36.
48. Canner, P.L.; Berge, K.G.; Wenger, N.K.; Stamler, J.; Friedman, L.; Prineas, R.J.; Friedewald, W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol., 1986, 8, 1245-1255.
49. Carlson, L.A.; Rosenhamer, G.; Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand., 1988, 223, 405-418.
50. Blankenhorn, D.H.; Johnson, R.L.; Nessim, S.A.; Azen, S.P.; Sanmarco, M.E.; Selzer, R.H. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control. Clin. Trials, 1987, 8, 356-387.
51. Cashin-Hemphill, L.; Mack, W.J.; Pogoda, J.M.; Sanmarco, M.E.; Azen, S.P.; Blankenhorn, D.H. Beneficial effects of colestipolniacin on coronary atherosclerosis. A 4-year follow-up. JAMA, 1990, 264, 3013-3017.
52. Kane, J.P.; Malloy, M.J.; Ports, T.A.; Phillips, N.R.; Diehl, J.C.; Havel, R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA, 1990, 264, 3007-3012.
53. Brown, G.; Albers, J.J.; Fisher, L.D.; Schaefer, S.M.; Lin, J.T.; Kaplan, C.; Zhao, X.Q.; Bisson, B.D.; Fitzpatrick, V.F.; Dodge, H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med., 1990, 323, 1289-1298.
54. Sacks, F.M.; Pasternak, R.C.; Gibson, C.M.; Rosner, B.; Stone, P.H. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet., 1994, 344, 1182-1186.
55. Brown, B.G.; Zhao, X.Q.; Chait, A.; Fisher, L.D.; Cheung, M.C.; Morse, J.S.; Dowdy, A.A.; Marino, E.K.; Bolson, E.L.; Alaupovic, P.; Frohlich, J.; Albers, J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med., 2001, 345, 1583-1592.
56. Taylor, A.J.; Sullenberger, L.E.; Lee, H.J.; Lee, J.K.; Grace, K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebocontrolled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 2004, 110, 3512-3517.
57. Whitney, E.J.; Krasuski, R.A.; Personius, B.E.; Michalek, J.E.; Maranian, A.M.; Kolasa, M.W.; Monick, E.; Brown, B.G.; Gotto, A.M. Jr. A randomized trial of a strategy for increasing highdensity lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann. Intern. Med., 2005, 142, 95-104.
58. Taylor, A.J.; Lee, H.J.; Sullenberger, L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin., 2006, 22, 2243-2250.
59. Taylor, A.J.; Villines, T.C.; Stanek, E.J.; Devine, P.J.; Griffen, L.; Miller, M.; Weissman, N.J.; Turco, M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med., 2009, 361, 2113-22.
60. McKenney, J.M.; Jones, P.H.; Bays, H.E.; Knopp, R.H.; Kashyap, M.L.; Ruoff, G.E.; McGovern, M.E.; Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis, 2007, 192, 432-437.
61. Morgan, J.M.; Capuzzi, D.M.; Guyton, J.R. A new extendedrelease niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am. J. Cardiol., 1998, 82, 29U-34U.
62. Bermudez, V.; Cano, R.; Cano, C.; Bermudez, F.; Arraiz, N.; Acosta, L.; Finol, F.; Pabón, M.R.; Amell, A.; Reyna, N.; Hidalgo, J.; Kendall, P.; Manuel, V.; Hernández, R. Pharmacologic management of isolated low high-density lipoprotein syndrome. Am. J. Ther., 2008, 15, 377-388.
63. Yuan, G.; Al-Shali, K.Z.; Hegele, R.A. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ, 2007, 176, 1113-1120.
64. Ballantyne, C.M.; Davidson, M.H.; McKenney, J.; Keller, L.H.; Bajorunas, D.R.; Karas, R.H. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs. simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am. J. Cardiol., 2008, 101, 1428-1436.
65. Carlson, L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med., 2005, 258, 94-114.
66. Canner, P.L.; Furberg, C.D.; Terrin, M.L.; McGovern, M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol., 2005, 95, 254-257.
67. Elam, M.B.; Hunninghake, D.B.; Davis, K.B.; Garg, R.; Johnson, C.; Egan, D.; Kostis, J.B.; Sheps, D.S.; Brinton, E.A. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA, 2000, 284, 1263-1270.
68. Grundy, S.M.; Vega, G.L.; McGovern, M.E.; Tulloch, B.R.; Kendall, D.M.; Fitz-Patrick, D.; Ganda, O.P.; Rosenson, R.S.; Buse, J.B.; Robertson, D.D.; Sheehan, J.P. Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med., 2002, 162, 1568-1576.
69. Knopp, R.H.; Paramsothy, P.; Atkinson, B.; Dowdy, A. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am. J. Cardiol., 2008, 101, 48B-57B.
70. Knopp, R.H. Drug treatment of lipid disorders. N. Engl. J. Med., 1999, 341, 498-511.
71. Cannon, C.P. Combination therapy in the management of mixed dyslipidaemia. J. Intern. Med., 2008, 263, 353-365.
72. Bostom, A.G.; Cupples, L.A.; Jenner, J.L.; Ordovas, J.M.; Seman, L.J.; Wilson, P.W.; Schaefer, E.J; Castelli, W.P. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA, 1996, 276, 544-548.
73. Gordon, T.; Castelli, W.P.; Hjortland, M.C.; Kannel, W.B.; Dawber, T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med., 1977, 62, 707-714.
74. Polonsky, T.S.; Davidson, M.H. Reducing the residual risk of 3- hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am. J. Cardiol., 2008, 101, 27B-35B.
75. Brown, B.G.; Zhao, X.Q. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am. J. Cardiol., 2008, 101, 58B-62B.
76. Karas, R.H.; Kashyap, M.L.; Knopp, R.H.; Keller, L.H.; Bajorunas, D.R.; Davidson, M.H. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am. J. Cardiovasc. Drugs., 2008, 8, 69-81.
77. Barter, P.; Gotto, A.M.; LaRosa, J.C.; Maroni, J.; Szarek, M.; Grundy, S.M.; Kastelein, J.J.; Bittner, V.; Fruchart, J.C. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med., 2007, 357, 1301-1310.
78. Nicholls, S.J.; Tuzcu, E.M.; Sipahi, I.; Grasso, A.W.; Schoenhagen, P.; Hu, T.; Wolski, K; Crowe, T.; Desai, M.Y.; Hazen, S.L.; Kapadia, S.R.; Nissen, S.E. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA, 2007, 297,499-508.
79. Goldenberg, I.; Benderly, M.; Sidi, R.; Boyko, V.; Tenenbaum, A.; Tanne, D.; Behar, S. Relation of clinical benefit of raising highdensity lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am. J. Cardiol., 2009, 103, 41-45.
80. Shepherd, J.; Packard, C.J.; Patsch, J.R.; Gotto, A.M. Jr.; Taunton, O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J. Clin. Invest., 1979, 63,858-867.
81. Rubins, H.B.; Robins, S.J.; Collins, D.; Fye, C.L.; Anderson, J.W.; Elam, M.B.; Faas, F.H.; Linares, E.; Schaefer, E.J.; Schectman, G.; Wilt, T.J.; Wittes, J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 1999, 341, 410-418.
82. McPherson, R.; Frohlich, J.; Fodor, G.; Genest, J. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can. J. Cardiol., 2006, 22, 913-927.
83. Frick, M.H.; Elo, O.; Haapa, K.; Heinonen, O.P.; Heinsalmi, P.; Helo, P.; Huttunen, J.K.; Kaitaniemi, P.; Koskinen, P.; Manninen, V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med., 1987, 317, 1237-1245.
84. Gordon, D.J.; Probstfield, J.L.; Garrison, R.J.; Neaton, J.D.; Castelli, W.P.; Knoke, J.D.; Jacobs, D.R. Jr,; Bangdiwala, S.; Tyroler, H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989, 79, 8-15.
85. Scanu, A.M.; Bamba, R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am. J. Cardiol., 2008, 101, 44B-47B.
86. Stein, J.H.; Rosenson, R.S. Lipoprotein Lp(a) excess and coronary heart disease. Arch. Intern. Med., 1997, 157, 1170-1176.
87. Cobbaert, C.; Jukema, J.W.; Zwinderman, A.H.; Withagen, A.J.; Lindemans, J.; Bruschke, A.V. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group. J. Am. Coll. Cardiol., 1997, 30, 1491-1499.
88. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, Fruchart JC, Ducimetiere P; PRIME Study Group. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis, 2002, 16, 377-84.
89. AIM-HIGH Cholesterol Management Program. Available at: http://www.aimhigh-heart.com/PDFs/protocol.pdf. Accessed 06/3, 2009.
90. HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events. Available at: http://clinicaltrials.gov/ct2/show/record/NCT00461630. Accessed 6/3, 2009.
91. Coronary Drug Project report on clofibrate and niacin. Atherosclerosis, 1978, 30, 239-240.
92. Knopp, R.H. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Am. J. Cardiol., 1998, 82, 24U-28U.
93. Goldberg, R.B.; Jacobson, T.A. Effects of niacin on glucose control in patients with dyslipidemia. Mayo. Clin. Proc., 2008, 83, 470-478.
94. Vittone, F.; Chait, A.; Morse, J.S.; Fish, B.; Brown, B.G.; Zhao, X.Q. Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS). J. Clin. Lipidol., 2007, 1, 203-210.
95. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, März W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med., 2003, 163, 553-64.
96. Kamal-Bahl, S.J.; Burke, T.; Watson, D.; Wentworth, C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am. J. Cardiol., 2007, 99, 530-534.
97. Rubic, T.; Trottmann, M.; Lorenz, R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol., 2004, 67, 411-419.